Nascent Biotech, Inc. (NBIO)
OTCMKTS: NBIO · Delayed Price · USD
0.0899
0.00 (0.00%)
Jun 17, 2024, 2:30 PM EDT - Market closed

Company Description

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.

It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.

The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.

In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab.

Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Nascent Biotech, Inc.
Country United States
Industry Biotechnology
Sector Healthcare
CEO Sean Carrick

Contact Details

Address:
631 Us Hwy 1, Suite 407
North Palm Beach, Florida 33408
United States
Phone 612-961-5656
Website nascentbiotech.com

Stock Details

Ticker Symbol NBIO
Exchange OTCMKTS
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001622057
CUSIP Number 63108Q101
ISIN Number US63108Q1013
Employer ID 45-0612715
SIC Code 2834

Key Executives

Name Position
Sean Carrick President, Chief Executive Officer, Secretary and Director
Lowell Holden Chief Financial Officer, Chief Accounting Officer and Director
Dr. Mark C. Glassy Ph.D. Founder
Dr. Navpaul Singh M.D. Chief Medical Consultant

Latest SEC Filings

Date Type Title
Apr 8, 2024 EFFECT Notice of Effectiveness
Apr 3, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 2, 2024 UPLOAD Filing
Mar 29, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 26, 2024 UPLOAD Filing
Mar 15, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Feb 14, 2024 10-Q Quarterly Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 19, 2023 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report